Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Review, H2 2015 Is Released it Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder 1
(ADHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173369/attentiondeficit-hyperactivity-disorder-adhd-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173369/attention-deficit-hyperactivity-disorder-adhd-pipeline-review-h2-2015 Table of Contents
Introduction 7 Global Markets Direct Report Coverage 7 Attention Deficit Hyperactivity Disorder (ADHD) Overview 8 Therapeutics Development 9 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview 9 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis 10 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies 11 Attention Deficit Hyperactivity Universities/Institutes 15
Disorder
(ADHD)
-
Therapeutics
under
Investigation
by
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies 20 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes 24 Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 25 Alcobra Ltd 25 Amarantus Bioscience Holdings, Inc. 26 APeT Holding BV 27 2
Arbor Pharmaceuticals, LLC. 28 BCWorld Pharm Co. Ltd. 29 Collegium Pharmaceutical, Inc. 30 Curemark, LLC 31 Domain Therapeutics SA 32 DURECT Corporation 33 H. Lundbeck A/S 34 Heptares Therapeutics Limited 35 Highland Therapeutics, Inc. 36 Hisamitsu Pharmaceutical Co., Inc. 37 Integrative Research Laboratories Sweden AB 38 Intra-Cellular Therapies, Inc. 39 KemPharm, Inc. 40 Luc Therapeutics, Inc. 41 Medgenics Inc. 42 Merck & Co., Inc. 43 Neos Therapeutics, Inc. 44 NeuroDerm Ltd. 45 Neurovance, Inc. 46 P2D Bioscience 47 Polleo Pharma Limited 48 Reviva Pharmaceuticals Inc. 49 Samyang Biopharmaceuticals Corporation 50 Shire Plc 51 Signature Therapeutics, Inc 52 Sunovion Pharmaceuticals Inc. 53
3
Supernus Pharmaceuticals, Inc. 54 Taisho Pharmaceutical Holdings Co., Ltd. 55 Tris Pharma, Inc. 56 Vernalis Plc 57 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 58 Assessment by Monotherapy Products 58 Assessment by Combination Products 59 Assessment by Target 60 Assessment by Mechanism of Action 63 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 (nicotine + opipramol hydrochloride) - Drug Profile 69 amfetamine XR - Drug Profile 70 AR-08 - Drug Profile 71 BCWPE-003 - Drug Profile 72 BLI-1008 - Drug Profile 73 BNC-375 - Drug Profile 74 CB-8411 - Drug Profile 75 centanafadine IR - Drug Profile 76 centanafadine SR - Drug Profile 77 CM-4612 - Drug Profile 78 CTX-1301 - Drug Profile 79 CTX-1302 - Drug Profile 80 dasotraline - Drug Profile 81 dextroamphetamine - Drug Profile 83 dextroamphetamine MR - Drug Profile 84 4
eltoprazine - Drug Profile 85 etiguanfacine - Drug Profile 87 guanfacine hydrochloride ER - Drug Profile 88 histamine dihydrochloride - Drug Profile 90 HTL-1071 - Drug Profile 91 IRL-752 - Drug Profile 92 ITI-214 - Drug Profile 93 KP-415 CR - Drug Profile 94 lisdexamfetamine dimesylate - Drug Profile 96 Metadoxine ER - Drug Profile 100 methylphenidate hydrochloride - Drug Profile 102 methylphenidate hydrochloride - Drug Profile 103 methylphenidate hydrochloride MR - Drug Profile 104 methylphenidate hydrochloride SR - Drug Profile 106 methylphenidate hydrochloride XR - Drug Profile 107 MGS-0028 - Drug Profile 108 molindone hydrochloride ER - Drug Profile 109 NFC-1 - Drug Profile 110 niacinamide CR - Drug Profile 111 NT-0201 - Drug Profile 112 P-001 - Drug Profile 113 PBF-509 - Drug Profile 114 PD-2005 - Drug Profile 116 PD-2007 - Drug Profile 117 PFR-08001 - Drug Profile 118 PFR-8026 - Drug Profile 119
5
RP-5063 - Drug Profile 120 SHP-465 - Drug Profile 121 Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile 122 Small Molecules to Agonize GPR88 for Attention Deficit Hyperactivity Disorder and Schizophrenia - Drug Profile 123 Small Molecules to Agonize NMDA2D for ADHD - Drug Profile 124 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 125 Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 126 Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile 127 TRI-102 - Drug Profile 128 V-81444 - Drug Profile 129 viloxazine hydrochloride - Drug Profile 130 vortioxetine hydrobromide - Drug Profile 131 VU-0238429 - Drug Profile 134 Attention Deficit Hyperactivity Disorder (ADHD) - Recent Pipeline Updates 135 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 170 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 175 Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 176 Featured News & Press Releases 176 Appendix 183 Methodology 183 Coverage 183 Secondary Research 183 Primary Research 183 Expert Panel Validation 183 Contact Us 183 Disclaimer 184
6
Read More http://www.idatainsights.com/reports-landing-page.php?id=173369/attention-deficithyperactivity-disorder-adhd-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
7
8